Cover Image

Worldwide population prevalence and impact of sub‐diagnostic gastrointestinal symptoms

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Olafur S. Palsson, Jan Tack, Douglas A. Drossman, Boris Le Nevé, Laurent Quinquis, Rim Hassouna, Johannah Ruddy, Carolyn B. Morris, Ami D. Sperber, Shrikant I. Bangdiwala, Magnus Simrén
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Letter: Social work and clinical synergy—Optimizing health interventions for elderly DGBI populations: Authors' reply
by: Ami D. Sperber, et al.
Published: (2024)

Gas‐Related Symptoms in the General Population: Prevalence, Impact and Associated Factors in a Survey of the United States, the United Kingdom, and Mexico
by: Olafur S. Palsson, et al.
Published: (2025)

Prevalence and Burden of Fatigue Across Disorders of Gut–Brain Interaction: Results From the Rome Foundation Global Epidemiology Study
by: Fleur Veldman, et al.
Published: (2026)

Symptom profiles compatible with disorders of gut‐brain interaction (DGBI) in organic gastrointestinal diseases: A global population‐based study
by: Tom van Gils, et al.
Published: (2024)

Functional Dyspepsia and Its Subgroups: Prevalence and Impact in the Rome IV Global Epidemiology Study
by: J. Tack, et al.
Published: (2025)

Bloating, Visible Abdominal Distension, and Other Intestinal Gas‐Related Symptoms in Irritable Bowel Syndrome and Functional Dyspepsia
by: Tom van Gils, et al.
Published: (2026)

Disorders of the gut‐brain interaction among European people with obesity: Prevalence and burden of compatible symptoms
by: Chloé Melchior, et al.
Published: (2025)

Factors Associated With Abdominal Pain in Patients With Active and Quiescent Ulcerative Colitis: A Multicohort Study
by: Tom van Gils, et al.
Published: (2024)

Clinical Trial: Study to Investigate the Efficacy and Safety of the Alpha‐2‐Delta Ligand PD‐217,014 in Patients With Irritable Bowel Syndrome
by: Lesley A. Houghton, et al.
Published: (2025)

Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission
by: Arta Aliu, et al.
Published: (2024)

Letter: Extreme diagnostic delay due to misdiagnosis of gastrointestinal tuberculosis later diagnosed as postoperative Crohn's disease
by: Abhirup Chatterjee, et al.
Published: (2024)

Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply
by: Arta Aliu, et al.
Published: (2024)

Editorial: Gastrointestinal symptoms—A world of differences
by: Kevin W. Olden
Published: (2024)

Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras
by: Daniel Tassone, et al.
Published: (2024)

Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors
by: Matthew J. Townsend, et al.
Published: (2024)

Letter: Post‐endoscopic management after upper gastrointestinal bleeding—Replenishment of iron loss
by: Palle Bager, et al.
Published: (2024)

Letter: Reflections on the role of over‐the‐scope clips in high‐risk upper gastrointestinal bleeding
by: Yajie Wang, et al.
Published: (2024)

Comparative Study on Burden, Features and Determinants of Disorders of Gut‐Brain Interaction Between Southern Europe and the Rest of Continent: Results From the Rome Foundation Global Epidemiology Study
by: Giovanni Marasco, et al.
Published: (2026)

The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes
by: Lana Bridi, et al.
Published: (2024)

A prospective study on the prevalence of at‐risk MASH in patients with type 2 diabetes mellitus in the United States
by: Nikita Mittal, et al.
Published: (2024)

Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis ‐ prevalence, clinical impact, economic implications and management strategies
by: Pegah Golabi, et al.
Published: (2024)

Letter: Over‐the‐scope clips in patients at high risk of re‐bleeding following upper gastrointestinal tract bleeding—The magic bullet for everyone?
by: Gabriel Allo, et al.
Published: (2024)

Letter: Light in the lumen—The expanding role of intestinal ultrasound for functional symptoms in inflammatory bowel disease
by: R. M. Mathias, et al.
Published: (2024)

Editorial: Diagnosis of GERD in patients with extra‐oesophageal symptoms–still a long way to go…
by: Sabine Roman, et al.
Published: (2024)

Letter: Over‐the‐scope clips in patients at high risk of rebleeding following upper gastrointestinal tract bleeding—The magic bullet for everyone? Authors'reply
by: Kai Song, et al.
Published: (2024)

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
by: Yewan Park, et al.
Published: (2024)

Editorial: Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low‐dose rivaroxaban or the combination: Secondary analysis of the COMPASS randomised controlled trial
by: Kanika Sehgal, et al.
Published: (2024)

Applying Lyon consensus criteria in the work‐up of patients with extra‐oesophageal symptoms – A multicentre retrospective study
by: Francesco Calabrese, et al.
Published: (2024)

Editorial: Diagnosis of GERD in patients with extra‐oesophageal symptoms—still a long way to go… Authors' reply'
by: Francesco Calabrese, et al.
Published: (2024)

Letter: Using non‐invasive fibrosis tests and emerging diagnostics to enhance the accuracy of liver fibrosis staging in MASLD patients
by: Wenjun Meng, et al.
Published: (2024)

Low socioeconomic status exacerbates unmet health‐related needs in patients with autoimmune hepatitis
by: Carolyn Singleton, et al.
Published: (2024)

The deep abdominal ultrasound transducer (DAX) increases the success rate and diagnostic accuracy of shear wave elastography for liver fibrosis assessment in patients with obesity—A prospective biopsy‐controlled study
by: David J. M. Bauer, et al.
Published: (2024)

Diagnostic classification systems for disorders of gut‐brain interaction should include psychological symptoms
by: Michael P. Jones, et al.
Published: (2024)

Use of a Non‐Endoscopic Capsule‐Sponge Triage Test for Reflux Symptoms: Results From the NHS England Prospective Real‐World Evaluation
by: Vlasios Gourgiotis, et al.
Published: (2025)

Featured Cover
by: Kai Markus Schneider, et al.
Published: (2025)

The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET‐NASH
by: Brent A. Neuschwander‐Tetri, et al.
Published: (2025)

Pain is a cardinal symptom cutting across Rome IV anatomical categories in disorders of gut‐brain interaction: A network‐based approach
by: Helen Burton‐Murray, et al.
Published: (2024)

No value of non‐selective beta‐blockers after TIPS‐insertion
by: Anja Tiede, et al.
Published: (2024)

Editorial: The future of managing drug induced liver injury
by: Amanda Nicoll
Published: (2024)

Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply
by: Vibeke Strande, et al.
Published: (2024)